Pfizer has announced strategic partnerships with Icon and Parexel, which will become strategic service providers for the American drug giant's clinical trials, for a period of five years starting from June 2011. The new partnership will be fully implemented over a period of 18-24 months. The alliances with Icon and Parexel reflect Pfizer's commitment to strengthen the performance of its innovative core of products. "We conducted a thorough selection process to find the right partners - says John Hubbard, senior vice president of Development Operations at Pfizer - and chose Icon and Parexel for the strength of their services and their constant commitment to compliance with quality and regulatory dictates". Pfizer will maintain scientific ownership of clinical development processes and monitor quality standards, safety and regulatory compliance.
June 8, 2011 – Pharmakronos
